Modulating AAV-Mediated Immune Response Depending on Route of Administration & Underlying Disease

Time: 11:30 am
day: Day 2 Tracks 2 AM


  • Consideration for prophylactic immunomodulation/immunosuppression depending on AAV-based gene therapy route of administration
  • Finding a subtle balance between safe immunomodulation and sufficient suppression of AAV-driven immune response
  • Additional safety considerations as they relate to immunosuppression when treating frail patient populations